Drugs / ALD-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01273337 | Mar 2011 → Jul 2014 | middle cerebral artery infarction | Aldagen | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALD-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01273337 ↗ |
| Modality | Cell therapy | “ALD-401 is an enriched population of aldehyde dehydrogenase-bright stem cells, capable of reducing neurological deficits in animal models.” PMID 30586746 ↗ Jan 2019 |